Murphy Matthew B.
Known title: General CounselCIK: 0001865778
Murphy Matthew B.'s purchase track record
Murphy Matthew B. has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/4/2025 | NAUT | $13K | +217.5% | +274.2% | +5.1% |
| 8/12/2022 | NAUT | $28K | -28.0% | -30.8% | -4.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| NAUT | ▲ Buy | Open Market | 20,000 | $13K | 9/4/2025 | View on chart |
| NAUT | ▲ Buy | Open Market | 7,500 | $21K | 8/15/2022 | View on chart |
| NAUT | ▲ Buy | Open Market | 2,500 | $7K | 8/12/2022 | View on chart |
| NAUT | ▲ Buy | Grant | 10,000 | $33K | 5/12/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Roth Capital initiates coverage on NAUT with $3.50 target
Roth Capital began tracking Nautilus Biotechnology with a Buy rating and a price target of $3.50. This new analyst note adds to the current consensus, where the average target from two analysts is $4.00. The stock is currently trading within its 52-week range of $0.72 to $4.31.
Roth Capital initiates coverage on NAUT with $3.50 target. Roth Capital began tracking Nautilus Biotechnology with a Buy rating and a price target of $3.50. This new analyst note adds to the current consensus, where the average target from two analysts is $4.00. The stock is currently trading within its 52-week range of $0.72 to $4.31.